LOS ALTOS, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in two upcoming investor conferences in December 2023.
Noble Capital Markets 19th Annual Emerging Growth Equity Conference (NobleCon)
Presentation: Monday, December 4, 2023 at 3:30 pm ET
Boca Raton, FL
A high-definition video webcast of the presentation will be available the following day on the Unicycive website under the Investors section: Events and Presentations.
2023 Benchmark Discovery One-on-One Investor Conference
December 7, 2023
New York, NY
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. For more information, please visit Unicycive.com and follow us on LinkedIn and YouTube.
Investor Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
(650) 543-5470
| Last Trade: | US$0.77 |
| Daily Change: | -0.006 -0.77 |
| Daily Volume: | 3,543,211 |
| Market Cap: | US$79.820M |
May 14, 2025 April 01, 2025 March 31, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
